However it is an important clinical presentation that physicians have to be aware of as timely intervention and appropriate therapy can alter clinical outcome in such patients. Methods: Here, we Enzalutamide datasheet report 57 year lady of Malay descent, who presented with odynophagia and few oral lesions with no cutaneous or pharyngeal involvement and was found to have newly diagnosed pemphigus vulgaris after undergoing a diagnostic esophagogastroduodenoscopy (OGD). She was initially treated as for presumed oropharyngeal candidiasis

and failed to improve with a one week course of oral fluconazole. Results: Diagnostic OGD showed the presence of characteristic bullous blisters in the esophagus, commonly seen in pemphigus vulgaris. She then underwent a biopsy of her lip ulcers which confirmed the diagnosis. The patient

was started on a course of oral prednisolone with marked improvement of her symptoms. To date, she remains well Conclusion: By highlighting this unusual presentation we hope to draw attention to the rarer presentations of pemphigus so that these manifestations can be recognised early and uneccessary investigations, treatment and costs can be avoided. Key Word(s): 1. pemphigus vulgaris; 2. esophagaus; 3. vesicobullous; Presenting Author: MK-8669 IMAM SUPRIANTO Additional Authors: SUYATA., SYADRA BARDIMAN, FUAD BAKRY Corresponding Author: IMAM SUPRIANTO Affiliations: Moehammad Hoesin Hospital Objective: Chronic gastritis is a localized or diffuse chronic inflammation of the lining of the stomach, histopathologically characterized by infiltration of lymphocytes and plasma cells in the mucosa. The imbalance between aggressive and defensive factors leads to this condition. Teprenone is a systemic cytoprotective PAK6 agent used to repair gastric mucosal lesions by increasing the synthesis, secretion, and mucus viscosity, increasing the gastric phospholipids, prostaglandin E2, prostacyclin and heat shock protein. The purpose of this study was to determine the effectiveness of teprenone as an

adjunct in the treatment of chronic gastritis Methods: This study was a double blind randomized clinical trial in the form of add on, which conducted at the outpatient clinic of Gastroenterology and Hepatology, Department of Internal Medicine Moehammad Hoesin Hospital Palembang, from June 2011 until February 2012. Patients were divided into 2 groups: the group given ranitidine, antacids, placebo (RAP) and the group given ranitidine, antacids, teprenone (RAT) for 4 weeks. Effectiveness assessed by clinical improvement, endoscopy, histopathology, inflammatory cells and Helicobacter Pylori. Data were analyzed using SPSS version 17 with the X2 and T test. Results: Of the 40 patients who participated in this study, 12 men and 28 women, there were statistically significant differences in the RAT groups in the improvement of clinical symptoms, endoscopy, histopathology, inflammatory cells and Helicobacter Pylori (P < 0.05).